

APC anti-human CD319 (CRACC)

Catalog # / Size: 2259050 / 100 tests
2259045 / 25 tests

Clone: 162.1

Isotype: Mouse IgG2b, κ


Immunogen: CRACC-Human IgG1 fusion protein

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific




Human peripheral blood lymphocytes were stained with CD3 FITC and CD319 (clone 162.1) APC (top) or mouse IgG2b, κ APC isotype control (bottom).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Application References:

1. Bouchon A, *et al.* 2001. *J. Immunol.* 167:551721.
2. Tassi I and Colonna M. 2005. *J. Immunol.* 175:79968002.
3. Veillette A. 2006. *Immunol. Rev.* 214:2234.

Description: CD319 is a single-pass type I transmembrane glycoprotein, expressed on NK cells, subsets of mature dendritic cells, activated B cells, and cytotoxic lymphocytes, but not in promyelocytic, B or T cell lines. Expression is highest in the spleen, lymph nodes, and peripheral blood leukocytes, and lowest in bone marrow. Additionally, it is expressed in the small intestine, stomach, appendix, lung, and trachea. CD319 is tyrosine phosphorylated in activated NK cells and is associated with 19 and 39 kD proteins. CD319 has homology with the CD2 family of receptors within the Ig superfamily. Some of the CD2 members stimulate cytotoxicity through the CD319 associated protein.

Antigen References:

1. Bouchon A, *et al.* 2001. *J. Immunol.* 167:551721.
2. Tassi I and Colonna M. 2005. *J. Immunol.* 175:79968002.
3. Veillette A. 2006. *Immunol. Rev.* 214:2234.